Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228) | UDP-3-O-acyl-GlcNAc deacetylase | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Chlamydia trachomatis | UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase | Get druggable targets OG5_132025 | All targets in OG5_132025 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | maternal embryonic leucine zipper kinase | 0.2847 | 0.584 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase MARK2 | 0.1418 | 0.1617 | 0.0074 |
Loa Loa (eye worm) | hypothetical protein | 0.1408 | 0.1585 | 0.0156 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1418 | 0.1617 | 0.0037 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1418 | 0.1617 | 0.0037 |
Trichomonas vaginalis | CAMK family protein kinase | 0.4255 | 1 | 1 |
Loa Loa (eye worm) | CAMK/CAMKL/MELK protein kinase | 0.4255 | 1 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase MARK2 | 0.1418 | 0.1617 | 0.0074 |
Schistosoma mansoni | serine/threonine kinase | 0.4255 | 1 | 1 |
Echinococcus multilocularis | calcium activated potassium channel | 0.1418 | 0.1617 | 0.0074 |
Echinococcus multilocularis | maternal embryonic leucine zipper kinase | 0.2847 | 0.584 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1418 | 0.1617 | 0.0037 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1418 | 0.1617 | 0.0037 |
Brugia malayi | Kinase associated domain 1 family protein | 0.1408 | 0.1585 | 0.0156 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1418 | 0.1617 | 0.0037 |
Chlamydia trachomatis | UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase | 0.0871 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.172 nM | BindingDB_Patents: Enzyme Assay. IC50 determination in the LpxC enzyme assay was carried out in a similar manner to that described by Malikzay et al in the 2006 Poster, Screening LpxC (UDP-3-O(R-3-hydroxymyristoyl)-GlcNAc deacetylase) using BioTrove Rapid Fire HTS Mass Spectrometry (aNew Lead Discovery and bInflammation and Infectious Disease, cStructural Chemistry, Schering-Plough Research Institute, Kenilworth, N.J. 07033, (BioTrove, Inc. 12 Gill St., Suite 4000, Woburn, Mass. 01801). Briefly, Pseudomonas aeruginosa LpxC enzyme (0.1 nM) purified from E. coli-overexpressing bacteria was incubated at 25° C. in a final volume of 50 ul containing 0.5 uM UDP-3-O(R-3-hydroxydecanoyl)-N-acetylglucosamine, 1 mg/mL BSA, and 50 mM sodium phosphate buffer, pH 8.0 in the presence and absence of inhibitor compound. At the end of 1 hour, 5 ul of 1N HCl was added to stop the enzyme reaction; the plates were centrifuged, and then processed with the BioTrove Rapidfire HTMS Mass Spectrometry System. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.